CPX-351 in Down syndrome-associated Myeloid Leukemia: Results and Prognostic Factors from the Phase 3 ML-DS 2018 Trial. Laszig S, Diederichs A, Salzmann-Manrique E, Schuschel K, et al. Blood 2025 Oct 21:blood.2025030775. doi: 10.1182/blood.2025030775.

Read + Share

Amedeo Smart

Independent Medical Education

Laszig S, Diederichs A, Salzmann-Manrique E, Schuschel K, et al. CPX-351 in Down syndrome-associated Myeloid Leukemia: Results and Prognostic Factors from the Phase 3 ML-DS 2018 Trial. Blood 2025 Oct 21:blood.2025030775. doi: 10.1182/blood.2025030775.
PMID: 41118594